MX2015008627A - Derivados de acido boronico y usos terapeuticos de los mismos. - Google Patents
Derivados de acido boronico y usos terapeuticos de los mismos.Info
- Publication number
- MX2015008627A MX2015008627A MX2015008627A MX2015008627A MX2015008627A MX 2015008627 A MX2015008627 A MX 2015008627A MX 2015008627 A MX2015008627 A MX 2015008627A MX 2015008627 A MX2015008627 A MX 2015008627A MX 2015008627 A MX2015008627 A MX 2015008627A
- Authority
- MX
- Mexico
- Prior art keywords
- acid derivatives
- boronic acid
- therapeutic uses
- preparation
- disclosed
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749204P | 2013-01-04 | 2013-01-04 | |
| US201361780855P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/010107 WO2014107536A1 (en) | 2013-01-04 | 2014-01-02 | Boronic acid derivatives and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008627A true MX2015008627A (es) | 2015-09-23 |
Family
ID=51061420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008627A MX2015008627A (es) | 2013-01-04 | 2014-01-02 | Derivados de acido boronico y usos terapeuticos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9132140B2 (enExample) |
| EP (1) | EP2941247A4 (enExample) |
| JP (1) | JP6324409B2 (enExample) |
| KR (1) | KR20150103270A (enExample) |
| CN (1) | CN104981239B (enExample) |
| AU (1) | AU2014204046B2 (enExample) |
| BR (1) | BR112015016002A2 (enExample) |
| CA (1) | CA2894892A1 (enExample) |
| EA (1) | EA201591004A1 (enExample) |
| MX (1) | MX2015008627A (enExample) |
| TW (1) | TW201431865A (enExample) |
| WO (1) | WO2014107536A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
| AU2013355110B2 (en) | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP2941246A4 (en) * | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2985626T3 (es) | 2014-05-05 | 2024-11-06 | Melinta Therapeutics Inc | Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos |
| SMT201900611T1 (it) | 2014-05-05 | 2020-01-14 | Rempex Pharmaceuticals Inc | Sintesi di sali boronati e usi degli stessi |
| CN106459096B (zh) * | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| MX2016016666A (es) * | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| ES2761778T3 (es) * | 2014-12-19 | 2020-05-21 | Rempex Pharmaceuticals Inc | Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105116076B (zh) * | 2015-09-28 | 2017-06-30 | 苏州二叶制药有限公司 | 一种头孢地嗪钠有关物质的检测方法 |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| DK3478693T3 (da) | 2016-06-30 | 2021-09-20 | Qpex Biopharma Inc | Boronsyrederivater og terapeutiske anvendelser deraf |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| IL268981B2 (en) | 2017-03-06 | 2023-09-01 | Venatorx Pharmaceuticals Inc | Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof |
| PL3621615T3 (pl) | 2017-05-12 | 2024-03-25 | Enanta Pharmaceuticals, Inc. | Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania |
| EP3630782A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019009369A1 (ja) * | 2017-07-06 | 2019-01-10 | 大日本住友製薬株式会社 | イミン誘導体 |
| TW201906616A (zh) * | 2017-07-06 | 2019-02-16 | 日商大日本住友製藥股份有限公司 | 醯胺衍生物 |
| JP7377545B2 (ja) * | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ， インコーポレイテッド | ボロン酸誘導体およびその合成 |
| CN109696429A (zh) * | 2018-01-30 | 2019-04-30 | 湖南师范大学 | AO-CoOOH纳米荧光探针及其制备方法和应用 |
| AU2019256351B2 (en) * | 2018-04-20 | 2024-02-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN118638140A (zh) | 2018-04-27 | 2024-09-13 | 住友制药株式会社 | 氧代取代化合物 |
| JP7328254B2 (ja) | 2018-05-02 | 2023-08-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤を含むテトラゾール及びその使用方法 |
| EP3802551A4 (en) | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP4049680A4 (en) | 2019-10-25 | 2024-01-10 | Sumitomo Pharma Co., Ltd. | NEW SUBSTITUTED CONDENSED RING CONNECTION |
| BR112023017203A2 (pt) | 2021-04-13 | 2023-11-07 | Tuojie Biotech Shanghai Co Ltd | Derivado de ácido bórico que age como inibidor de beta-lactamase |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
| US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| CA1283404C (en) | 1986-07-01 | 1991-04-23 | Shigeru Sanai | Cephalosporin compounds, processes for their preparation and antibacterial agents |
| ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
| US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
| US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| WO1998056392A1 (en) | 1997-06-13 | 1998-12-17 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| AU3124300A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
| WO2000035905A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| AU765020B2 (en) | 1999-09-25 | 2003-09-04 | Smithkline Beecham Plc | Piperazine derivatives as 5-HT1B antagonists |
| AU762935B2 (en) | 1999-10-28 | 2003-07-10 | Merck & Co., Inc. | Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| WO2002022137A1 (en) | 2000-09-12 | 2002-03-21 | Shoichet Brian K | β-LACTAM ANALOGS AND USES THEREFOR |
| AU2002212614B2 (en) | 2000-09-14 | 2006-12-07 | Basilea Pharmaceutica Ag | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| US6586615B1 (en) | 2001-01-10 | 2003-07-01 | Bristol-Myers Squibb Company | α-aminoboronic acids prepared by novel synthetic methods |
| DE10118698A1 (de) | 2001-04-17 | 2002-11-07 | Jerini Ag | Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP2003229277A (ja) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | 発光素子材料およびそれを用いた発光素子並びに装置 |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| JP3714948B2 (ja) | 2002-09-11 | 2005-11-09 | 呉羽化学工業株式会社 | アミン化合物及びその用途 |
| WO2004039859A1 (ja) | 2002-10-30 | 2004-05-13 | Sumitomo Chemical Company, Limited | 高分子化合物およびそれを用いた高分子発光素子 |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| EP1581472A2 (en) | 2002-12-20 | 2005-10-05 | MIGENIX Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| JP4233365B2 (ja) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | アザジオール錯体化合物、及び該化合物を用いる光記録媒体 |
| US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
| WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
| TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
| US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
| US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| MX2007010138A (es) | 2005-02-22 | 2007-09-27 | Teva Pharma | Preparacion de rosuvastatina. |
| US9184428B2 (en) | 2005-03-15 | 2015-11-10 | Uchicago Argonne Llc | Non-aqueous electrolytes for lithium ion batteries |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| CA2629570C (en) | 2005-12-07 | 2012-11-27 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
| CN101420854B (zh) | 2006-02-16 | 2013-08-07 | 安纳考尔医药公司 | 作为抗炎药的含硼的小分子 |
| AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
| WO2008116813A2 (en) | 2007-03-23 | 2008-10-02 | Basilea Pharmaceutica Ag | Combination medicaments for treating bacterial infections |
| GB0719366D0 (en) | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| AU2008321443A1 (en) * | 2007-11-13 | 2009-05-22 | Novartis Ag | Beta-lactamase inhibitors |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| MY162532A (en) | 2008-01-18 | 2017-06-15 | Merck Sharp & Dohme | Beta-lactamase inhibitors |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100256092A1 (en) | 2008-05-12 | 2010-10-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2009139834A1 (en) | 2008-05-13 | 2009-11-19 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
| WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
| AR076667A1 (es) | 2009-05-12 | 2011-06-29 | Novartis Int Pharm Ltd | Inhibidores de beta-lactamasa |
| EP2440050A4 (en) | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| EP2458995A1 (en) | 2009-07-28 | 2012-06-06 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
| CA2828114A1 (en) | 2010-02-26 | 2011-09-01 | Gary Igor DMITRIENKO | Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof |
| US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
| RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
| TW201221518A (en) | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| EP2508506A1 (en) * | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
| HK1206261A1 (en) | 2011-12-22 | 2016-01-08 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| CA2862710A1 (en) | 2012-01-09 | 2013-07-18 | University Of Tromso | Therapeutic boron-containing compounds |
| WO2013122888A2 (en) | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| AU2013355110B2 (en) | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP2941246A4 (en) | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
-
2014
- 2014-01-02 CA CA2894892A patent/CA2894892A1/en not_active Abandoned
- 2014-01-02 BR BR112015016002A patent/BR112015016002A2/pt not_active IP Right Cessation
- 2014-01-02 AU AU2014204046A patent/AU2014204046B2/en not_active Ceased
- 2014-01-02 CN CN201480003994.0A patent/CN104981239B/zh active Active
- 2014-01-02 MX MX2015008627A patent/MX2015008627A/es unknown
- 2014-01-02 EA EA201591004A patent/EA201591004A1/ru unknown
- 2014-01-02 EP EP14735389.0A patent/EP2941247A4/en not_active Withdrawn
- 2014-01-02 KR KR1020157021054A patent/KR20150103270A/ko not_active Withdrawn
- 2014-01-02 WO PCT/US2014/010107 patent/WO2014107536A1/en not_active Ceased
- 2014-01-02 JP JP2015551762A patent/JP6324409B2/ja not_active Expired - Fee Related
- 2014-01-02 US US14/146,643 patent/US9132140B2/en active Active
- 2014-01-03 TW TW103100230A patent/TW201431865A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014107536A1 (en) | 2014-07-10 |
| EA201591004A1 (ru) | 2016-02-29 |
| CN104981239A (zh) | 2015-10-14 |
| JP2016505619A (ja) | 2016-02-25 |
| BR112015016002A2 (pt) | 2017-07-11 |
| AU2014204046A1 (en) | 2015-07-16 |
| US20140194384A1 (en) | 2014-07-10 |
| CN104981239B (zh) | 2019-01-04 |
| CA2894892A1 (en) | 2014-07-10 |
| EP2941247A4 (en) | 2017-02-08 |
| AU2014204046B2 (en) | 2017-02-23 |
| EP2941247A1 (en) | 2015-11-11 |
| JP6324409B2 (ja) | 2018-05-16 |
| KR20150103270A (ko) | 2015-09-09 |
| US9132140B2 (en) | 2015-09-15 |
| TW201431865A (zh) | 2014-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| GB201106743D0 (en) | Novel compounds | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| IN2015DN03998A (enExample) | ||
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| ZA201505318B (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
| MX363530B (es) | Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo. | |
| IN2014DN10449A (enExample) | ||
| TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| HK1212978A1 (zh) | 芥子酸的新型衍生物 | |
| MX345263B (es) | Formulación de pexiganan estable. | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| WO2015044434A3 (de) | FLUOR-9-METHYL-ß-CARBOLINE | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина |